Press coverage about BioCryst Pharmaceuticals (NASDAQ:BCRX) has been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioCryst Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.5070661002074 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- BioCryst Pharmaceuticals Announces Secondary Offering (feedproxy.google.com)
- After-Hours Stock Movers 09/11: (WDC) (LAYN) Higher; (BCRX) (PTLA) (FDC) Lower (more…) (streetinsider.com)
- BRIEF-BioCryst Pharmaceuticals announces underwritten public offering (feeds.reuters.com)
- Jefferies Group Analysts Lower Earnings Estimates for BioCryst Pharmaceuticals, Inc. (BCRX) (americanbankingnews.com)
- BioCryst Pharmaceuticals, Inc. (BCRX) registers a price change of 0.61% while Loxo Oncology, Inc. (LOXO) finishes … – Stocks Gallery (stocksgallery.com)
Several equities analysts recently commented on the stock. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Sunday, May 28th. ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 8th. BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $15.00 price objective (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 5th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. BioCryst Pharmaceuticals has an average rating of “Hold” and an average target price of $9.13.
Shares of BioCryst Pharmaceuticals (NASDAQ BCRX) traded down 5.826% during trading on Tuesday, reaching $5.415. 2,597,129 shares of the company traded hands. The stock’s market capitalization is $435.52 million. BioCryst Pharmaceuticals has a 12-month low of $3.75 and a 12-month high of $9.25. The firm’s 50-day moving average is $4.82 and its 200-day moving average is $6.11.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The company had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $5.79 million. During the same period in the prior year, the firm earned ($0.22) EPS. BioCryst Pharmaceuticals’s quarterly revenue was down 35.4% on a year-over-year basis. On average, equities analysts predict that BioCryst Pharmaceuticals will post ($0.75) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “BioCryst Pharmaceuticals (BCRX) Given Media Sentiment Score of 0.18” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.themarketsdaily.com/2017/09/12/biocryst-pharmaceuticals-bcrx-given-media-sentiment-score-of-0-18.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.